Results 11 to 20 of about 292,142 (337)

Opioid Agonist Treatment for Patients With Dependence on Prescription Opioids

JAMA, 2017
Are different opioid agonist treatments (eg, methadone vs buprenorphine) associated with differences in efficacy for treating prescription opioid dependence, and is long-term maintenance of opioid agonist treatment associated with differences in efficacy compared with opioid taper or psychological treatments alone?For patients who are dependent on ...
Nielsen, S, Larance, B, Lintzeris, N
openaire   +6 more sources

A retrospective cohort study evaluating correlates of deep tissue infections among patients enrolled in opioid agonist treatment using administrative data in Ontario, Canada.

PLoS ONE, 2020
ObjectiveThe objective of this study was to evaluate the relationship between individual characteristics and deep tissue infections in patients enrolled in opioid agonist treatment in Ontario, Canada.MethodsA retrospective cohort study was conducted on ...
Kristen A Morin, Chad R Prevost, Joseph K Eibl, Michael T Franklyn, Alexander R Moise, David C Marsh   +5 more
doaj   +2 more sources

Global opioid agonist treatment: A review of clinical practices by country.

Addiction, 2020
AIMS We assessed how opioid agonist treatment (OAT) for opioid use disorder (OUD), specifically methadone and buprenorphine, including buprenorphine-naloxone, is delivered in routine clinical practice, with a focus on factors that affect access to and ...
Harry Jin, S. Larney, B. Marshall, L. Degenhardt, J. Strang, M. Hickman, D. Fiellin, R. Ali, J. Bruneau   +8 more
semanticscholar   +3 more sources

Reducing stigma within pharmacy opioid agonist treatment encounters.

Stigma and Health
Although community pharmacies are the primary site for opioid agonist treatment (OAT) dispensing in Australia, little is known about the service experiences of consumers and pharmacists. This study aimed to explore how OAT consumers experienced social inclusion and stigma in this setting, and how pharmacists can dispense OAT in ways that minimise ...
T. Caruana
openaire   +3 more sources

Opioid Medical Detoxification Compared to Opioid Agonist Treatment during Pregnancy: A Scoping Review. [PDF]

Healthcare (Basel)
Opioid use disorder (OUD) is highly prevalent, affecting up to 1% of pregnancies. The current standard of care for the management of OUD during pregnancy has been maintained with opioid agonist treatment (OAT), using either methadone or buprenorphine. OAT use has been associated with a risk of neonatal abstinence syndrome (NAS), which requires a longer
Ordean A, DeVuono I.
europepmc   +3 more sources

Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis.

JAMA psychiatry, 2021
Importance Mortality among people with opioid dependence is higher than that of the general population. Opioid agonist treatment (OAT) is an effective treatment for opioid dependence; however, there has not yet been a systematic review on the ...
Thomas Santo, Brodie Clark, M. Hickman, J. Grebely, G. Campbell, L. Sordo, Aileen Z Chen, L. Tran, C. Bharat, P. Padmanathan, Gráinne Cousins, Julie Dupouy, Erin A. Kelty, R. Muga, B. Nosyk, J. Min, R. Pavarin, M. Farrell, L. Degenhardt   +18 more
semanticscholar   +1 more source

What is the benefit of inconsistent opioid agonist treatment in patients with prescription opioid use disorder?

European Psychiatry, 2023
Introduction Studies consistently show that patients with prescription opioid use disorder (OUD) respond to buprenorphine treatment. Few studies have followed these patients in the long-term.
R. Weiss, M. L. Griffin
doaj   +1 more source

Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder

Addiction Science & Clinical Practice, 2023
Background Patients with opioid use disorder (OUD) frequently leave the hospital as patient directed discharges (PDDs) because of untreated withdrawal and pain.
A. Thakrar, Tanya J. Uritsky, C. Christopher, A. Winston, Kaitlin Ronning, Anna L. Sigueza, A. Caputo, Rachel McFadden, J. Olenik, J. Perrone, M. Delgado, M. Lowenstein, P. Compton   +12 more
semanticscholar   +1 more source

Opioid Substitution: More than Only Methadone!

European Psychiatry, 2022
Opioid misuse and its rising rates of morbidity and associated mortality is an increasing area of concern worldwide. The licit/illicit consumption of opioids ranging from plant-based substances and pharmaceutical drugs (particularly analgesia) to the new
M. Torrens
doaj   +1 more source

Should I Stay or Should I Go? A Qualitative Exploration of Stigma and Other Factors Influencing Opioid Agonist Treatment Journeys

International Journal of Environmental Research and Public Health, 2023
Highlights OAT treatment journeys in our sample were influenced by a broad range of individual, social and structural factors, with stigma presenting a pervasive barrier to treatment retention and recovery. Pharmacies were a particularly strong source of
V. Carlisle, O. Maynard, D. Bagnall, M. Hickman, J. Shorrock, K. Thomas, J. Kesten   +6 more
semanticscholar   +1 more source